iShares Biotechnology ETF news

The ETF demonstrates strong performance with 51.48% one-year returns and 23.89% year-to-date returns. It offers broad diversification with 252 holdings, competitive expense ratio of 0.44%, and substantial assets under management ($10.5 billion), making it a reasonable option for healthcare sector exposure.

IBB offers lower fees (0.44% expense ratio) and broader diversification with 248 holdings, making it more accessible for risk-averse investors. However, it has underperformed FBT significantly over the past decade (118% ten-year return, 8.1% CAGR) and exhibits higher top-heavy concentration despite having more holdings, limiting its appeal for growth-focused investors.

Presented as an alternative option with $10.28 billion in assets and 0.44% expense ratio, but no comparative advantage or disadvantage highlighted.

Presented as a viable alternative with larger assets ($10.47 billion) and a lower expense ratio of 0.44%, making it a competitive option in the biotech ETF space.

Climbed 2.5% as healthcare sector outperformed.

Recommended as an alternative biotech ETF with broader international exposure, 250+ positions, and compelling 40%+ 12-month returns despite recent YTD underperformance, offering exposure to patent cliff opportunities.

Mentioned as a diversified alternative for broader biotech exposure; no specific performance data or recommendation provided beyond being a sector option.

Mentioned as significant ETF exposure holder but no specific performance impact or commentary provided in the article.

Presented as a diversified alternative investment option for biotech exposure with modest performance (28% YoY) and low expense ratio; mentioned for risk mitigation purposes rather than as a primary investment thesis.